Trials / Completed
CompletedNCT00502385
Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AML
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 54 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study will be conducted across multiple European centres to assess the safety and tolerability of multiple doses of AZD2171 in patients with AML.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD2171 |
Timeline
- Start date
- 2004-04-01
- First posted
- 2007-07-17
- Last updated
- 2011-01-21
Source: ClinicalTrials.gov record NCT00502385. Inclusion in this directory is not an endorsement.